Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of lenalidomide in treating
young patients with recurrent, progressive, or refractory CNS tumors. Lenalidomide may stop
the growth of CNS tumors by blocking blood flow to the tumor. It may also stimulate the
immune system in different ways and stop tumor cells from growing.